29 mayo 2015
Promising clinical trial results show activity of the investigational anti-cancer agent ONT-380 against HER2+ breast cancer, in one case specifically against brain metastases and in another case in overall survival of heavily pretreated HER2+ breast cancer patients.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/uOVeVPmF9vE/150529131505.htm
